Abbott has officially launched its AVEIR VR single-chamber ventricular leadless pacemaker in India, offering an innovative solution for patients with slow heart rhythms. Approved by both India’s Central Drugs Standard Control Organization (CDSCO) and the U.S. FDA, this advanced pacemaker is set to transform cardiac care in the country.

Unlike traditional pacemakers, which require a chest incision, a generator pocket, and cardiac leads, the AVEIR VR pacemaker eliminates these complexities. It is implanted directly into the heart’s right ventricle through a minimally invasive catheter-based procedure via the groin. This approach eliminates chest incisions, wires, and generator pockets, significantly reducing procedural risks and recovery time.

The device features unique mapping capabilities, enabling physicians to assess electrical signals in the heart and identify the optimal placement before implantation. Additionally, the pacemaker’s extended battery life provides long-term benefits, making it suitable for a broader range of patients. Notably, the AVEIR VR is designed for retrieval, allowing replacement or adjustment to therapy if needed, ensuring flexibility in treatment.

Speaking on the launch, Abbott highlighted the device’s potential to redefine pacemaker therapy. With its cutting-edge technology, AVEIR VR empowers clinicians to deliver precision care while enhancing patient outcomes.

This launch underscores Abbott’s commitment to bringing innovative healthcare solutions to India, setting a new benchmark in cardiac care.